.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
EMPA-KIDNEY broadened the evidence for SGLT2 inhibition by enrolling patients with chronic kidney disease across a wide range of diabetes status and eGFR. Empagliflozin reduced the risk of kidney disease progression or cardiovascular death compared with placebo, supporting a kidney-protective effect beyond glucose lowering. The study is especially relevant to general physicians because CKD is frequently detected late and often coexists with diabetes and hypertension. For practice, the major opportunity is earlier identification using eGFR and urine albumin testing, followed by risk-based therapy and monitoring. SGLT2 inhibitors should be integrated with renin–angiotensin system blockade where indicated and with appropriate blood-pressure, glycemic and cardiovascular management. Volume status and renal function need review around initiation and during acute illness. EMPA-KIDNEY strengthens the concept that nephroprotection is a central component of cardiometabolic medicine rather than a specialist-only concern.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
EMPA-KIDNEY broadened the evidence for SGLT2 inhibition by enrolling patients with chronic kidney disease across a wide range of diabetes status and eGFR. Empagliflozin reduced the risk of kidney disease progression or cardiovascular death compared with placebo, supporting a kidney-protective effect beyond glucose lowering. The study is especially relevant to general physicians because CKD is frequently detected late and often coexists with diabetes and hypertension. For practice, the major opportunity is earlier identification using eGFR and urine albumin testing, followed by risk-based therapy and monitoring. SGLT2 inhibitors should be integrated with renin–angiotensin system blockade where indicated and with appropriate blood-pressure, glycemic and cardiovascular management. Volume status and renal function need review around initiation and during acute illness. EMPA-KIDNEY strengthens the concept that nephroprotection is a central component of cardiometabolic medicine rather than a specialist-only concern.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
